Interview on Ontada research presented at ISPOR 2024.
Overall survival (OS) is a foundational measure in cancer clinical trials. But when it comes to capturing OS in real-world studies, the question of which data source to use can be tricky. An electronic helath record may not show when a patient has died, and some databases have a lag between a person’s actual death and when that event shows up in the records.
Kat Aguilar, MPH | Image: Ontada
Investigators from Ontada examined the completeness of different real-world data (RWD) sources in recording mortality/vitality and their appropriateness for research, with results reported May 8, 2024, at ISPOR—The Professional Society for Health Economics and Outcomes Research. Kat Aguilar, MPH, director, real world research for Ontada, presented the findings and spoke about them with Evidence-Based Oncology.
As Aguilar explained, there will always be some patients for whom date of death is not recorded in structured EHR data. “We need to find a way to address it,” she said.
One theme of the ISPOR meeting was whether data are “fit for purpose,” ie, whether data can be used to answer the question at hand. Aguilar said there 2 tests for determining this: appropriateness and efficiency.
To test RWD sources for these qualities, the Ontada team examined their completeness among patients with cancers known to have high mortality rates: glioblastoma multiforme (GBM) and metastatic pancreatic cancer (mPC). Adult patients with diagnosed with GBM or mPC between January 1, 2019, and December 31, 2019, were followed through August 31, 2023. Then mortality data were sourced from EHRs and from the following external sources:
As Aguilar explained, at times it’s important to estimate OS with data sources that are closer to real time than the NDI allows. By evaluating these other sources, she said, “the study shows we’ve got about a 90% capture rate” which meets the test of appropriateness, for “near perfect agreement” with the NDI.
Inclusion of the NDI did add a 5% “lift in terms of the data capture,” but there were also deaths not recorded in the NDI that the FDW and other RWD sources were able to catch, Aguilar said.
Methods and results. Investigators first confirmed vitality status via chart abstraction on January 15, 2023. Then OS was estimated, with and without NDI data, for both the GBM and mPC populations. Results showed the following:
Investigators found that using only structured EHR, the FDW, and commercial sources, 993 or 91.4% of all death records were captured. Among the GBM population, the median OS was 13.7 months (95% CI, 11.4-14.7), and 13.5 months (95% CI, 10.8-14.4) without and without the NDI data, respectively.
With 91% of all death records captured without chart abstraction or the NDI, the investigators concluded, “survival estimation without these sources can be a fit-for-purpose and scalable option for oncology research.”
Reference
Aguilar K, Wang Y, Sykes C, et al. Fit-for-purpose and scalable strategy to address mortality completeness for oncology research: comparison of multiple real-world sources with the National Death Index. Value Health. 2024;27(6):S1,CO188.
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More